Yes, you know what? I don't really have the details. The guys worked out in the markets. But like I said, it was kind of a tuneup, so I don't think was -- it's certainly not across-the-board. It would be -- and on the product lines, there's no one product line that took a big increase. It was more, like I say, a tuneup, take a little bit here, take a little bit there. And it's either where we're at in that market or where our product lines are against each other in that market. So with some markets, we have Cemplank, Hardie and Color all targeted in a market. So you have to make sure that delta between those product lines is right in that. And that's been mainly what we've been kind of working on. Now our increase this year, as we've covered before, has been mainly around getting our tactical pricing straightened out. And so you're seeing that kind of increase a little bit every quarter as it gets cleaner and cleaner. So that's why the 5 this quarter, of course, it's -- again, it's a quarter so the variance is higher. But we are getting cleaner pricing still quarter-to-quarter. And I assume that impact kind of goes away in the next 2 quarters, I would say. We'll probably be as clean as we're ever going to be with our tactical pricing. But as far as details on the overall price increase, I apologize. I really don't have them. It was probably a very long document because like I said, it was very market and product-specific, product line-specific end markets. So mainly what I focused on is what was driving it and what does it average out to. So it averages out, like I said, in that low 2%, depending on what the mixes look like next year and what was driving it, yes, okay.
Jason Harley Steed - JP Morgan Chase & Co, Research Division: Okay, and I appreciate that. And would it be fair to say, just to get on your comment regarding price increases being exterior for next year. You're not looking a Backer increase for the coming fiscal year?